Compare WPRT & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WPRT | MIRA |
|---|---|---|
| Founded | 1995 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.6M | 32.1M |
| IPO Year | 2006 | 2023 |
| Metric | WPRT | MIRA |
|---|---|---|
| Price | $1.83 | $0.69 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $3.66 | N/A |
| AVG Volume (30 Days) | 54.3K | ★ 163.3K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.35 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.54 | $0.60 |
| 52 Week High | $2.55 | $2.45 |
| Indicator | WPRT | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 39.02 |
| Support Level | $1.83 | $0.61 |
| Resistance Level | $2.09 | $0.82 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 23.05 | 25.94 |
Westport Fuel Systems Inc is an organization engaged in the engineering, manufacturing, and supply of alternative fuel systems and components for transportation applications. It has three reportable segments: High-Pressure Controls, Heavy-Duty OEM, and Cespira. It derives maximum revenue from Heavy-Duty OEM segment. Heavy-Duty OEM segment's products include HPDI related fuel system solutions and components. Geographically, the company operates in Europe, America and Asia, of which it generates maximum revenue from Europe. It also develops and supplies advanced LPG, CNG, LNG and H2 systems and components for OEM (original equipment manufacturer) D-OEM (delayed oem) and After Market (retrofit market) world-wide.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.